Abstract
This article describes procedural elements involved in ensuring the integrity of bioanalytical data. These elements can be divided into 3 areas. First, there are those ensuring the integrity of the analyte until analysis, through correct sample collection, handling, shipment, and storage procedures. Incorrect procedures can lead to loss of analyte via instability, addition of analyte through contamination or instability of related metabolites, or changes in the matrix composition that may adversely affect the performance of the analytical method. Second, the integrity of the sample identity needs to be maintained to ensure that the final result reported relates to the individual sample that was taken. Possible sources of error include sample mixup or mislabeling, or errors in data handling. Finally, there is the overall integrity of the documentation that supports the analysis, and any prestudy validation of the method. This includes a wide range of information, from paper and electronic raw data, through standard operating procedures and analytical procedures and facility records, to study plans and final reports. These are critical to allow an auditor or regulatory body to reconstruct the study.
Keywords: Sample integrity, audit trails, bioanalytical methods validation, GLP
Full Text
The Full Text of this article is available as a PDF (533.8 KB).
References
- 1.Organisation for Economic Co-operation and Development . OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring No 13. Paris, France: ENV,JM,MONO; 2002. [Google Scholar]
- 2.Food and Drug Administration . Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, FDA, CDER; 2001. [Google Scholar]
- 3.Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 2007;9:E30–E42. doi: 10.1208/aapsj0901004. [DOI] [PubMed] [Google Scholar]
- 4.Food and Drug Administration . FDA Compliance Program Guidance Manual. Chapter 48: Program 7348.001. Rockville, MD: FDA; 2000. [Google Scholar]
- 5.Food and Drug Administration . Guidance for Industry Part 11, Electronic Records: Electronic Signatures—Scope and Application. Rockville, MD: US Department of Health and Human Services, FDA, CDER; 2003. [Google Scholar]
- 6.Food and Drug Administration . 21CFR320—Bioavailability and Bioequivalence Requirements (Drugs for Human Use) Rockville, MD: US Department of Health and Human Services, FDA, CDER; 2002. [Google Scholar]
- 7.Committee for Proprietary Medicinal Products . Note for Guidance on Investigation of Bioavailability and Bioequivalence. Canary Wharf, London: CPMP,EWP,QWP-1401/98; 2001. [Google Scholar]